These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

580 related items for PubMed ID: 23937987

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 3. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.
    Cermak J, Jonasova A, Vondrakova J, Walterova L, Hochova I, Siskova M, Neuwirtova R.
    Hemoglobin; 2011 Jun; 35(3):217-27. PubMed ID: 21599434
    [Abstract] [Full Text] [Related]

  • 5. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
    Goldberg SL.
    Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of deferasirox in myelodysplastic syndromes.
    Breccia M, Alimena G.
    Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
    [Abstract] [Full Text] [Related]

  • 7. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
    Metzgeroth G, Dinter D, Schultheis B, Dorn-Beineke A, Lutz K, Leismann O, Hehlmann R, Hastka J.
    Ann Hematol; 2009 Apr; 88(4):301-10. PubMed ID: 18758781
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
    Maurillo L, Breccia M, Buccisano F, Voso MT, Niscola P, Trapè G, Tatarelli C, D'Addosio A, Latagliata R, Fenu S, Piccioni AL, Fragasso A, Aloe Spiriti MA, Refrigeri M, Criscuolo M, Musto P, Venditti A.
    Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
    [Abstract] [Full Text] [Related]

  • 10. Iron chelation therapy in myelodysplastic syndrome - Cui bono?
    Tefferi A, Stone RM.
    Leukemia; 2009 Aug; 23(8):1373. PubMed ID: 19672273
    [No Abstract] [Full Text] [Related]

  • 11. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 12. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome.
    Ghoti H, Fibach E, Westerman M, Gordana O, Ganz T, Rachmilewitz EA.
    Br J Haematol; 2011 Apr; 153(1):118-20. PubMed ID: 21332711
    [Abstract] [Full Text] [Related]

  • 13. Iron chelation therapy for transfusional iron overload: a swift evolution.
    Musallam KM, Taher AT.
    Hemoglobin; 2011 Apr; 35(5-6):565-73. PubMed ID: 21910602
    [Abstract] [Full Text] [Related]

  • 14. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
    Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C, EPIC study investigators.
    Leuk Res; 2010 Sep; 34(9):1143-50. PubMed ID: 20451251
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S, Ebadi M, Ghazizadeh F, Arzanian MT, Shamsian B, Abdollah Gorji F.
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M, Carrara P, Pinto V, Forni GL.
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract] [Full Text] [Related]

  • 19. Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes.
    Wimazal F, Nösslinger T, Baumgartner C, Sperr WR, Pfeilstöcker M, Valent P.
    Eur J Clin Invest; 2009 May; 39(5):406-11. PubMed ID: 19320908
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.